维生素C葡萄糖苷的研究现状及发展前景

维生素C葡萄糖苷是卫生署公布认可的美白添加剂之一,利用糖基转移酶的特异性转糖基作用进行生物转化合成是目前维生素C葡萄糖苷的唯一生产途径。对维生素c葡萄糖苷的生产方法进行了讨论,着重阐述了其制备（生物转化合成法）、纯化及结晶三大生产工艺的国内外研究现状,指出国内实现维生素C葡萄糖苷工业化生产的发展方向。     

维生素D_3与雄性生殖

维生素D3的经典作用是调节体内钙、磷的代谢平衡和维持骨的健康,有证据显示维生素D3也可调节动物生殖。维生素D代谢酶可合成和降解活性维生素D3及其代谢中间产物,活性维生素D3通过结合至目标组织的维生素D受体(vitamin D receptor,VDR)以发挥其生物学作用。VDR和维生素D代谢酶在雄性生殖系统中表达,表明维生素D3在雄性生殖生物学中起关键作用。本文对维生素D3与雄性生殖的研究进展作一综述,以期为推进维生素D3影响雄性生殖的分子机制和临床治疗男性不育的研究提供理论依据。     

1,25-二羟维生素D3的生物学效应

1,25-二羟维生素D3是维生素D3的活性形式,其生物学效应是由基因组与非基因组两种机制介导的。维生素D3除了具有钙磷代谢调节作用外,还具有其他更为广泛的生物学效应。1,25-二羟维生素D3能够抑制多种类型细胞的增殖,诱导细胞的凋亡和分化,调节机体免疫系统功能,保护中枢神经系统,以及保护基因等。     

一株蟾毒灵转化菌株的筛选鉴定与转化条件优化

【背景】微生物转化是对天然产物进行结构修饰的重要手段,具有催化反应快、选择性强、反应条件易控制和污染小等特点。许多微生物能够对蟾毒配基类化合物进行生物转化,在不同位置进行结构修饰,并且产生毒性减弱的活性衍生物。【目的】筛选蟾毒灵生物转化菌株,以期发现活性更好、毒性降低的化合物。【方法】利用蟾毒灵为底物筛选其生物转化菌株,通过HPLC (High performance liquid chromatography)/LC-MS (Liquid chromatograph-mass spectrometer)鉴定转化产物;对可生物转化蟾毒灵的菌株进行菌落形态观察和分子生物学鉴定,并优化发酵条件提高转化率,同时测试该菌株对其他甾体化合物的转化作用。【结果】筛选获得一株蟾毒灵转化菌,经形态学与ITS (Internal transcribed spacer)分析鉴定为Naganishia属菌,转化产物为3-去氢蟾毒灵。该菌株生物转化的培养基最适底物浓度为8 mg/L,最适初始pH值为6.5,最佳接种量为3%,最佳转化时间为96 h,最终转化率为48.3%。该菌株可将雌酮E1转化为雌二醇E2,也可将雌二醇E2逆向转化为E1。【结论】首次发现Naganishia属菌株对甾体类化合物具有转化活性,其产生的弱细胞毒性的转化产物3-去氢蟾毒灵有望成为高效、安全的强心药物。微生物转化法选择性高、反应条件温和、操作简单,为大量制备活性化合物3-去氢蟾毒灵提供了一条简便易行的道路,也为更多甾体化合物结构修饰提供了可能。     

大剂量维生素D3补充对糖尿病大鼠胰岛及肌肉细胞组织学的影响

目的：探讨大剂量维生素D3补充对糖尿病（DM）大鼠Lees指数及胰岛、肌肉细胞组织学的影响。方法：高糖高脂喂养结合注射链脲佐菌素的方法制备DM模型,不同浓度的维生素D3灌胃6w,HE染色观察胰岛和肌肉形态。结果：125倍和200倍维生素D3组大鼠Lees指数比DM组明显升高。各维生素D干预组胰岛和骨骼肌组织学形态明显改善。结论：适量维生素D3补充能增加DM大鼠Lees指数,恢复异常的胰岛和肌肉形态。     

活性维生素D3对大鼠系膜增生性肾炎PCNA的影响

目的:研究活性维生素D3对大鼠系膜增生性肾小球肾炎的作用及机制.方法:应用抗大鼠胸腺细胞免疫血清(Anti-thymocyte serum,ATS)抗体一次性尾静脉注射复制大鼠系膜增生性肾小球肾炎(Mesangial Proliferative Glomerulonephritis,MsPGN)模型,将实验大鼠分为三组对照组(A组)、模型组(B组)、活性维生素D3治疗组(C组),分别与1、3、7、14天每组各处死6只大鼠,并采用Envision免疫组化法、RT-PCR法,观察PCNA蛋白、PCNAmRNA及中性粒细胞在肾小球中的表达情况.结果:肾炎组增殖细胞核抗原(Proliferating cell nuclear Antigen,PCNA)蛋白、PCNAmRNA及肾小球中中性粒细胞计数明显高于对照组(p＜0.01),并随着时间延长逐渐增高,到第7天达到高峰,第14天有下降的趋势.活性维生素D3治疗组PCNA蛋白、PCNAmRNA及肾小球中中性粒细胞计数的表达均较低(p＜0.01),其中第3、7、14天表达均显著减少(p＜0.05).PCNA蛋白、PCNAmRNA、中性粒细胞计数各指标之间呈均成正相关.结论:活性维生素D3可以抑制系膜细胞的增生,其作用机制可能是抑制炎症细胞浸润、PCNAmRNA及其蛋白的表达.     

酵母细胞生物转化反式—肉桂酸生产L—苯丙氨酸的研究

据文献调查,搜集了国内可能相关的30株酵母,进行生物转化反式-肉桂酸(t-Ca) 生产L-苯丙氨酸 (L-Phe) 的微生物筛选研究,并对部分菌株生物转化能力,即苯丙氨酸解氨酶 (PAL,EC _(4、3、1、5) 活性水平进行了初步评估。筛选结果是:22株酵母具有转化 t-Ca 生成 L-Phe 的能力,转化率在2—67％范围。选出7株酵母研究在液体培养条件下细胞生长和PAL活性的时间过程关系,PAL 活性范围在 2.3—14.4x10~(-s)u/m g细胞干重。深红酵母 (Rhodotorularubra) AS2.166作为生物转化制备实经菌株,在静止细胞和固定化细胞批式反应条件下,结果获得L-Phe分离产率分别为42.0％,28.7％。     

假丝酵母C-5的不对称生物还原作用研究

生命与手性密切相关,凡涉及到生命现象和生理活性物质几乎都离不开有关分子的空间立体构型问题,不同构型的手性分子具有不同的生理活性。利用酶反应的立体专一性,用生物转化法取代部分传统的化学方法,可以很方便地制备具有所需手性中心的化合物。因此,近年来生物转化...     

天然活性先导化合物生物转化研究进展

天然活性先导化合物生物转化是利用生物催化剂(如：酶、微生物、动植物细胞)将加入到生物反应系统中的天然活性先导化合物进行特异性的分子结构修饰以获得高效、低毒新化合物的方法。该方法可以有效地提高已知的天然活性先导化合物的活性、降低毒副作用、改善水溶性和生物利用度,也可以用来生产具有重要应用价值的微量天然活性先导化合物,同时可用于药物代谢机制的研究。国内外学者已经针对甾体、醌类、黄酮类、萜类等化合物开展了天然活性先导化合物生物转化研究,筛选出一批有重要应用价值的生物转化反应类型,但针对天然活性先导化合物生物转化的机制、生物转化过程工程以及生物转化产物活性等方面的研究较少。将现代生命科学技术(如：生物催化剂的定向改造、高通量筛选、组合生物转化、非水相生物转化)引入天然活性先导化合物生物转化研究中,必将推进天然活性先导化合物的快速发展。     

北京市中小学生维生素D水平与血脂异常的相关性研究

目的：探讨北京市中小学生血清维生素D水平与血脂异常的相关性。 方法：数据来源于2015年北京市中小学生营养与健康状况监测。采用多阶段分层整群抽样方法于北京市3个城区、4个郊区每区选取小学、初中各4所学校共3 566名中小学生进行调查。抽取静脉血检测维生素D和血生化指标等,采用二元Logistic回归模型分析血清维生素D不足和缺乏对血脂异常发生风险的影响。 结果：在3 566名中小学生中,血脂异常的有735人（20.6%）,维生素D不足的有947人（26.6%）,维生素D缺乏的有824人（23.1%）。二元Logistic回归模型在调整了年龄、性别、地区、体型、尿酸和空腹血糖变量后,发现维生素D不足和维生素D缺乏对总血脂异常发生的风险没有影响;而与维生素D适宜者相比,维生素D不足降低了TC异常发生的风险,增加了TG异常发生的风险;与维生素D适宜者相比,维生素D缺乏降低了TC异常和LDL C异常发生的风险,增加了HDL C异常发生的风险。结论：北京市中小学生血脂异常、维生素D不足和缺乏的情况均较为严重,需引起重视;在该研究样本中,维生素D不足和缺乏对总血脂异常的发生风险没有影响;维生素D不足降低了TC异常发生的风险,增加了TG异常发生的风险;维生素D缺乏降低了TC异常和LDL C异常发生的风险,增加了HDL C异常发生的风险。维生素D与血脂异常的关系仍需进一步的研究加以证实。     

Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense

The role of vitamin D in innate immunity is increasingly recognized. Recent work has identified a number of tissues that express the enzyme 1alpha-hydroxylase and are able to activate vitamin D. This locally produced vitamin D is believed to have important immunomodulatory effects. In this paper, we show that primary lung epithelial cells express high baseline levels of activating 1alpha-hydroxylase and low levels of inactivating 24-hydroxylase. The result of this enzyme expression is that airway epithelial cells constitutively convert inactive 25-dihydroxyvitamin D(3) to the active 1,25-dihydroxyvitamin D(3). Active vitamin D that is generated by lung epithelium leads to increased expression of vitamin D-regulated genes with important innate immune functions. These include the cathelicidin antimicrobial peptide gene and the TLR coreceptor CD14. dsRNA increases the expression of 1alpha-hydroxylase, augments the production of active vitamin D, and synergizes with vitamin D to increase expression of cathelicidin. In contrast to induction of the antimicrobial peptide, vitamin D attenuates dsRNA-induced expression of the NF-kappaB-driven gene IL-8. We conclude that primary epithelial cells generate active vitamin D, which then influences the expression of vitamin D-driven genes that play a major role in host defense. Furthermore, the presence of vitamin D alters induction of antimicrobial peptides and inflammatory cytokines in response to viruses. These observations suggest a novel mechanism by which local conversion of inactive to active vitamin D alters immune function in the lung.     

Synthesis and biological activity of 3 beta-fluorovitamin D3: comparison of the biological activity of 3 beta-fluorovitamin D3 and 3-deoxyvitamin D3

The alteration in the biologic activity of the vitamin D3 molecule resulting from the replacement of a hydrogen atom with a fluorine atom is a subject of fundamental interest. To investigate this problem we synthesized 3 beta-fluorovitamin D3 6 and its hydrogen analog, 3-deoxyvitamin D3 7, and tested the biologic activity of each by in vitro and in vivo methods. Contrary to previous reports which showed that 3 beta-fluorovitamin D3 was as active as vitamin D3 in vivo, we found that the fluoro-analog was less active than vitamin D3. With regard to stimulation of intestinal calcium transport and bone calcium mobilization in the D-deficient hypocalcemic rat, 3 beta-fluorovitamin D3 showed significantly greater biologic activity than its hydrogen analog, 3-deoxyvitamin D3. In the organ-cultured, embryonic chick duodenum, 3 beta-fluorovitamin D3 was approx 1/1000th as active as the native hormone, 1,25-dihydroxyvitamin D3, while 3-deoxyvitamin D3 was inactive even at microM concentrations, in the induction of the vitamin D-dependent, calcium-binding protein. With regard to in vitro activity in displacing radiolabeled 25-hydroxyvitamin D3 from vitamin D binding protein and radiolabelled 1,25-dihydroxyvitamin D3 from a chick intestinal cytosol receptor, 3 beta-fluorovitamin D3 and 3 beta-deoxyvitamin D3 both showed very poor binding efficiencies when compared with vitamin D3. Our results show that the substitution of a fluorine atom for a hydrogen atom at the C-3 position of the vitamin D3 molecule results in a fluorovitamin 6 with significantly more biological activity than its hydrogen analog, 3-deoxyvitamin D3 7.     

Impaired glucose tolerance in vitamin D deficiency can be corrected by calcium

Vitamin D(3), via its active metabolite 1alpha,25-dihydroxyvitamin D(3), helps maintain normal calcium levels in the body. Apart from the maintenance of calcium homeostasis, the active form of vitamin D(3) is now known to be involved in a number of other functions including that of pancreatic beta cells. Low serum insulin levels and impaired glucose tolerance in a vitamin D-deficient state have been reported in experimental animals. Hypocalcemia is a major consequence of vitamin D deficiency. Whether the impairment observed is due to vitamin D deficiency per se or is secondary to low calcium is still a matter of controversy. The present study was conducted to delineate the roles of vitamin D and calcium in glucose intolerance associated with vitamin D deficiency in vivo. It was found that supplementation with either vitamin D(3) or high calcium alone to vitamin D-deficient rats could correct the defects. In addition, insulin sensitivity was found to be enhanced in the vitamin D-deficient group compared with vitamin D control or calcium-supplemented groups. Hence the present study demonstrates that calcium per se in the absence of vitamin D increases insulin secretion and normalizes intolerance to glucose seen in vitamin D deficiency.     

Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.

Serum Bone Gla Protein (BGP) levels were measured by both immunoradiometric assay (IRMA) and radioimmunoassay (RIA) to investigate the effect of intermittent 1,25(OH)2D3 administration to dialysis patients who could not tolerate an increase in an active vitamin D3 dose and/or calcium to control secondary hyperparathyroidism due to hypercalcemia. The administration of active vitamin D3 gradually increased the serum BGP to more than 3 times the original level by the 8th week. At the 12th week after starting the active vitamin D3 therapy, mean BGP was about twice the original level, which was about half the maximum level at the 8th week. The BGP (IRMA)/BGP (RIA) ratio was increased significantly at 4th and 8th weeks compared to the original level. During this period, serum calcium, phosphorous, or intact molecule PTH (I-PTH) levels showed insignificant changes, with a slight reduction in the mid molecule PTH (m-PTH) level, and a significant reduction in ALP. Serum BUN and creatinine levels were not changed significantly. These data suggest that BGP was increased through direct stimulation of osteoblasts by the active vitamin D3, and the increase was not due to deterioration of secondary hyperparathyroidism. The reduction of the increase in the BGP level at the 12th week with insignificant biochemical changes suggest that activation of osteoblasts by vitamin D3 may be transient. In conclusion, intermittent active vitamin D3 increases serum BGP, without deterioration of major biochemical changes even in patients with moderate to severe secondary hyperparathyroidism, although the increase may be transient. These facts suggest that the serum BGP of hemodialysis patients is controlled at least in part by active vitamin D3.(ABSTRACT TRUNCATED AT 250 WORDS)     

Biologically active metabolite of vitamin D3 from bone, liver, and blood serum

Radioactive metabolites present in bone, blood, liver, and feces of rats given (3)H vitamin D(3) have been isolated. Of these the aqueous soluble metabolite(s) from tissue and all those isolated from feces did not cure rickets in rats, while all the others were at least partially active in this regard. One of the metabolites proved to be as active as the parent vitamin in curing rickets and was found in large amounts in liver, blood, and bone. As much as 50-80% of the radioactivity in bone was found in this metabolite after a 500 IU oral dose of (3)H vitamin D(3). With 10 IU doses of 1,2-(3)H vitamin D(3), most of the radioactivity of the organs examined was found in this metabolite fraction. This metabolite appears to be more polar than vitamin D and is not an esterified form of the vitamin nor a complex of the vitamin with tissue lipids. Its possible role as the metabolically active form of the vitamin is discussed.     

Metabolism and biologica.

24R,24,25-Dihydroxyvitamin D3 is capable of inducing a minimal intestinal calcium transport response in chicks when compared to an equal amount of 25-hydroxyvitamin D3. 1,24,25-Trihydroxyvitamin D3 is also less active than 1,25-dihydroxyvitamin D3, and its activity is much shorter lived than that of 1,25-dihydroxyvitamin D3. A comparison of the metabolism of 25-hydroxy[26,27-3H]vitamin D3 and 24,25-dihydroxy[26,27-3H]vitamin D3 in the rat and chick shows that 24,25-dihydroxyvitamin D3 and 1,24,25-trihydroxyvitamin D3 disappear at least 10 times more rapidly from the blood and intestine of chicks. Furthermore, examination of the excretory products from both of these species demonstrates that chicks receiving a single dose of 24,25-dihydroxy[26,27-3H]vitamin D3 excrete 66% of the total radioactivity by 48 hours, whereas rats receiving the same dose excrete less than one-half that amount. These results demonstrate that 24,25-dihydroxyvitamin D3 is considerably less biologically active in the chick than in the rat, probably due to more rapid metabolism and excretion.     

Involvement of 1,25-dihydroxyvitamin D3 in regulating myocardial calcium metabolism: physiological and pathological actions

The role of the prohormone vitamin D3 in regulating calcium and phosphate metabolism in the intestine, kidney, and bone has been known for several decades. Recent studies have provided evidence that vitamin D3, may also play an important role in regulating metabolism in other organs, including heart. This role has been suggested by the identification of a specific receptor for 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the active metabolite of vitamin D3, in these tissues, as well as the presence of a 1,25(OH)2D3-dependent calcium binding protein. Although administration of excessive quantities of vitamin D3 has been shown in many studies to produce myocardial calcinosis and heart failure, the importance of vitamin D3 in regulating myocardial metabolism under normal conditions has only recently been demonstrated. The purpose of the present review is to assess the current status of research regarding the pathological and physiological actions of vitamin D3 on the heart. The initial section of this report will focus on the pathological effects of excessive vitamin D3 on cardiovascular function, while the latter sections will describe recent studies related to the involvement of 1,25(OH)2D3 in regulating calcium homeostasis in ventricular cells and the relationship between vitamin D3 and myocardial contractility.     

Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1

CYP27A1 is a mitochondrial cytochrome P450 which can hydroxylate vitamin D3 and cholesterol at carbons 25 and 26, respectively. The product of vitamin D3 metabolism, 25-hydroxyvitamin D3, is the precursor to the biologically active hormone, 1α,25-dihydroxyvitamin D3. CYP27A1 is attached to the inner mitochondrial membrane and substrates appear to reach the active site through the membrane phase. We have therefore examined the ability of bacterially expressed and purified CYP27A1 to metabolize substrates incorporated into phospholipid vesicles which resemble the inner mitochondrial membrane. We also examined the ability of CYP27A1 to metabolize 20-hydroxyvitamin D3 (20(OH)D3), a novel non-calcemic form of vitamin D derived from CYP11A1 action on vitamin D3 which has anti-proliferative activity on keratinocytes, leukemic and myeloid cells. CYP27A1 displayed high catalytic activity towards cholesterol with a turnover number (k(cat)) of 9.8 min(-1) and K(m) of 0.49 mol/mol phospholipid (510 μM phospholipid). The K(m) value of vitamin D3 was similar for that of cholesterol, but the k(cat) was 4.5-fold lower. 20(OH)D3 was metabolized by CYP27A1 to two major products with a k(cat)/K(m) that was 2.5-fold higher than that for vitamin D3, suggesting that 20(OH)D3 could effectively compete with vitamin D3 for catalysis. NMR and mass spectrometric analyses revealed that the two major products were 20,25-dihydroxyvitamin D3 and 20,26-dihydroxyvitamin D3, in almost equal proportions. Thus, the presence of the 20-hydroxyl group on the vitamin D3 side chain enables it to be metabolized more efficiently than vitamin D3, with carbon 26 in addition to carbon 25 becoming a major site of hydroxylation. Our study reports the highest k(cat) for the 25-hydroxylation of vitamin D3 by any human cytochrome P450 suggesting that CYP27A1 might be an important contributor to the synthesis of 25-hydroxyvitamin D3, particularly in tissues where it is highly expressed.     

The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice

The active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3), suppresses autoimmune disease in several animal models including experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The molecular mechanism of this immunosuppression is at present unknown. While 1alpha,25-dihydroxyvitamin D(3) is believed to function through a single vitamin D receptor, there are reports of other vitamin D receptors as well as a "nongenomic" mode of action. We have prepared the EAE model possessing the vitamin D receptor null mutation and determined if 1alpha,25-dihydroxyvitamin D(3) can suppress this disease in the absence of a functional vitamin D receptor. Vitamin D receptor null mice develop EAE although the incidence rate is one-half that of wild-type controls. The administration of 1alpha,25-dihydroxyvitamin D(3) had no significant effect on the incidence of EAE in the vitamin D receptor null mice, while it completely blocked EAE in the wild-type mice. We conclude that 1alpha,25-dihydroxyvitamin D(3) functions to suppress EAE through the well-known VDR and not through an undiscovered receptor or through a "nongenomic" mechanism.